Randomized Clinical Trial of Intravitreal Bevacizumab Versus Intravitreal Bevacizumab Combined With Losartan in the Treatment of Diabetic Macular Edema

Status

Completed

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02663141

Enrollment

Registered

2016-01-26

Start date

2015-06-30

Completion date

2016-06-30

Last updated

2016-07-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetic Macular Edema

Brief summary

The aim of this study is to determine whether oral losartan is effective in the treatment of diabetic macular edema (DME) as an adjuvant for intravitreal bevacizumab (IVB).

Interventions

DRUGLosartan

DRUGIntravitreal bevacizumab

DRUGPlacebo

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender

ALL

Healthy volunteers

Inclusion criteria

All type 2 diabetes mellitus patients with clinically significant macular edema(CSME), except those mentioned as

Design outcomes

Primary

Measure	Time frame
difference in ETDRS best-corrected visual acuity (BCVA) between arms	Within 6 months from therapy
Difference in frequency of intravitreal Bevacizumab injection between arms	Within 6 months from therapy

Secondary

Measure	Time frame
change in central macular thickness(measured by spectral domain optical coherence tomography)	Within 6 months from therapy

Countries

Iran

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026